Wednesday, July 8, 2026

pharma · Contraception · Chlamydia Trachomatis Infection · EVFM

Evofem Biosciences

Evofem Biosciences clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

San Diego, USA HQ
2015 Founded
39 Employees
Public company Type
EVFM · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2015
Employees
39
Programs
6
Drugs
2
Patents
8
Intelligence · Clinical Programs

Evofem Biosciences projects

5 ClinicalTrials.gov programs sponsored by Evofem Biosciences.

Evofem Biosciences has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AMPHORA

    Evofem Biosciences

    Contraception

    phase 3 small molecule completed

    1 trial
  2. Conceptrol

    Evofem Biosciences

    Contraception

    phase 3 small molecule completed

    1 trial
  3. EVO100

    Evofem Biosciences

    Chlamydia Trachomatis Infection

    phase 3 small molecule completed

    1 trial
  4. EVO100

    Evofem Biosciences

    Sexually Transmitted Diseases

    phase 3 small molecule completed

    1 trial
  5. LIPO-202

    Evofem Biosciences

    Central Abdominal Bulging

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

How many clinical projects does Evofem Biosciences have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.